Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

October 4, 2012

Conditions

Prostate CancerAdenocarcinoma of the ProstateHormone-resistant Prostate CancerStage IV Prostate Cancer

Interventions

DRUG

bicalutamide

Given orally

DRUG

raloxifene

Given orally

PROCEDURE

quality-of-life assessment

Ancillary study

Trial Locations (1)

Mayo Clinic In Arizona, Scottsdale